Ospemifene, vulvovaginal atrophy, and breast cancer

Gregory T. Wurz, Lin H. Soe, Michael W. DeGregorio

Research output: Contribution to journalArticle

41 Citations (Scopus)

Abstract

The incidence and severity of vulvovaginal atrophy (VVA) in postmenopausal breast cancer patients has a significant impact on quality of life. While the etiology of VVA is primarily related to low estrogen levels seen in menopause, women with breast cancer have an added risk of VVA induced by a combination of chemotherapy, hormonal therapy, and menopause. Ospemifene is a new, non-hormonal selective estrogen receptor modulator (SERM) triphenylethylene derivative that is effective in treating VVA in postmenopausal women. Although other SERMs have antagonistic effects on the vagina, ospemifene exerts an estrogen-like effect on the vaginal epithelium. This review will focus on data demonstrating the antiestrogenic activity of ospemifene in several unique breast cancer animal models, and the implications for utilizing ospemifene in patients with breast cancer suffering from VVA. Additional research addressing the expanded use of ospemifene in breast cancer patients is also warranted.

Original languageEnglish (US)
Pages (from-to)220-225
Number of pages6
JournalMaturitas
Volume74
Issue number3
DOIs
StatePublished - Mar 2013

Fingerprint

Atrophy
Breast Neoplasms
Selective Estrogen Receptor Modulators
Menopause
Estrogens
Chemotherapy
Vagina
Combination Drug Therapy
Animals
Epithelium
Animal Models
Quality of Life
Ospemifene
Derivatives
Incidence
Research
Therapeutics

Keywords

  • Antiestrogen
  • Breast cancer
  • Ospemifene
  • Vulvovaginal atrophy

ASJC Scopus subject areas

  • Obstetrics and Gynecology
  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Wurz, G. T., Soe, L. H., & DeGregorio, M. W. (2013). Ospemifene, vulvovaginal atrophy, and breast cancer. Maturitas, 74(3), 220-225. https://doi.org/10.1016/j.maturitas.2012.12.002

Ospemifene, vulvovaginal atrophy, and breast cancer. / Wurz, Gregory T.; Soe, Lin H.; DeGregorio, Michael W.

In: Maturitas, Vol. 74, No. 3, 03.2013, p. 220-225.

Research output: Contribution to journalArticle

Wurz, GT, Soe, LH & DeGregorio, MW 2013, 'Ospemifene, vulvovaginal atrophy, and breast cancer', Maturitas, vol. 74, no. 3, pp. 220-225. https://doi.org/10.1016/j.maturitas.2012.12.002
Wurz, Gregory T. ; Soe, Lin H. ; DeGregorio, Michael W. / Ospemifene, vulvovaginal atrophy, and breast cancer. In: Maturitas. 2013 ; Vol. 74, No. 3. pp. 220-225.
@article{a2df334fdadc440d9a528ee0affa96a5,
title = "Ospemifene, vulvovaginal atrophy, and breast cancer",
abstract = "The incidence and severity of vulvovaginal atrophy (VVA) in postmenopausal breast cancer patients has a significant impact on quality of life. While the etiology of VVA is primarily related to low estrogen levels seen in menopause, women with breast cancer have an added risk of VVA induced by a combination of chemotherapy, hormonal therapy, and menopause. Ospemifene is a new, non-hormonal selective estrogen receptor modulator (SERM) triphenylethylene derivative that is effective in treating VVA in postmenopausal women. Although other SERMs have antagonistic effects on the vagina, ospemifene exerts an estrogen-like effect on the vaginal epithelium. This review will focus on data demonstrating the antiestrogenic activity of ospemifene in several unique breast cancer animal models, and the implications for utilizing ospemifene in patients with breast cancer suffering from VVA. Additional research addressing the expanded use of ospemifene in breast cancer patients is also warranted.",
keywords = "Antiestrogen, Breast cancer, Ospemifene, Vulvovaginal atrophy",
author = "Wurz, {Gregory T.} and Soe, {Lin H.} and DeGregorio, {Michael W.}",
year = "2013",
month = "3",
doi = "10.1016/j.maturitas.2012.12.002",
language = "English (US)",
volume = "74",
pages = "220--225",
journal = "Maturitas",
issn = "0378-5122",
publisher = "Elsevier Ireland Ltd",
number = "3",

}

TY - JOUR

T1 - Ospemifene, vulvovaginal atrophy, and breast cancer

AU - Wurz, Gregory T.

AU - Soe, Lin H.

AU - DeGregorio, Michael W.

PY - 2013/3

Y1 - 2013/3

N2 - The incidence and severity of vulvovaginal atrophy (VVA) in postmenopausal breast cancer patients has a significant impact on quality of life. While the etiology of VVA is primarily related to low estrogen levels seen in menopause, women with breast cancer have an added risk of VVA induced by a combination of chemotherapy, hormonal therapy, and menopause. Ospemifene is a new, non-hormonal selective estrogen receptor modulator (SERM) triphenylethylene derivative that is effective in treating VVA in postmenopausal women. Although other SERMs have antagonistic effects on the vagina, ospemifene exerts an estrogen-like effect on the vaginal epithelium. This review will focus on data demonstrating the antiestrogenic activity of ospemifene in several unique breast cancer animal models, and the implications for utilizing ospemifene in patients with breast cancer suffering from VVA. Additional research addressing the expanded use of ospemifene in breast cancer patients is also warranted.

AB - The incidence and severity of vulvovaginal atrophy (VVA) in postmenopausal breast cancer patients has a significant impact on quality of life. While the etiology of VVA is primarily related to low estrogen levels seen in menopause, women with breast cancer have an added risk of VVA induced by a combination of chemotherapy, hormonal therapy, and menopause. Ospemifene is a new, non-hormonal selective estrogen receptor modulator (SERM) triphenylethylene derivative that is effective in treating VVA in postmenopausal women. Although other SERMs have antagonistic effects on the vagina, ospemifene exerts an estrogen-like effect on the vaginal epithelium. This review will focus on data demonstrating the antiestrogenic activity of ospemifene in several unique breast cancer animal models, and the implications for utilizing ospemifene in patients with breast cancer suffering from VVA. Additional research addressing the expanded use of ospemifene in breast cancer patients is also warranted.

KW - Antiestrogen

KW - Breast cancer

KW - Ospemifene

KW - Vulvovaginal atrophy

UR - http://www.scopus.com/inward/record.url?scp=84875434415&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84875434415&partnerID=8YFLogxK

U2 - 10.1016/j.maturitas.2012.12.002

DO - 10.1016/j.maturitas.2012.12.002

M3 - Article

C2 - 23332519

AN - SCOPUS:84875434415

VL - 74

SP - 220

EP - 225

JO - Maturitas

JF - Maturitas

SN - 0378-5122

IS - 3

ER -